Figure 2
CDCP1 expression is elevated in advanced UC and enriched in Ba/Sq subtype. (A) Expressional levels of CDCP1 in UC tissue compared to NAT. Data obtained from the TCGA BLCA data set. ****P < 0.0001. Statistical test: two-tailed unpaired t test. (B) Comparison of CDCP1 levels between the UC molecular subtypes from TCGA BLCA data set. ****P < 0.0001. Statistical test: one-way analysis of variance. (C) Visualization via scRNAseq analysis of the expressional levels of CDCP1, and different Lu subtype molecular markers (FGFR3, FOXA1, GATA3) and Ba/Sq subtype molecular markers (EGFR, KRT5, KRT14) in the UC cohort from Chen et al., 2020. (D) Representative images of tumors from the MIBC TMA showing tumors with CDCP1-low and CDCP1-high. Table showing the total number of MIBC tumors, CDCP1-low and CDCP1-high. (E) Percentage of tumors from the MIBC TMA which show a low or high CDCP1 expression, clustered on the base of the UC subtype. (F) Bar graphs indicating the expression of CK5 and CK14 in CDCP1-high tumors compared to CDCP1-low tumors. The expression is evaluated by IHC in the MIBC TMA. Error bars indicate SD. ****P < 0.0001. Statistical test: two-tailed unpaired t test. (G) Transcriptional expression of CDCP1 (TPM: transcripts per million reads) compared to CDCP1-low and CDCP1-high levels in the MIBC TMA confirming the correlation between CDCP1 transcripts and protein levels. (H) CDCP1 TPM across the UC subtypes showing the high expression of CDCP1 in the Ba/Sq subtype. Tumor samples are correspondent to the ones from the MIBC TMA. (I) Kaplan–Meier survival analysis of UC patients treated with chemotherapy stratified based on the semi-quantitative expression of CDCP1 (CDCP1-low: negative, weak; CDCP1-high: moderate, strong). *P < 0.05. Statistical test: Gehan–Breslow–Wilcoxon test.
